Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 10, 2010 - Issue 5
Submit an article Journal homepage
100
Views
4
CrossRef citations to date
0
Altmetric
Special Report

Challenges in funding diabetes care: a health economic perspective

Christian Weber Ernst Basler & Partner Inc., Zollikerstrasse 65, CH-8702 Zollikon, Switzerland. [email protected]
Pages 517-524 | Published online: 09 Jan 2014

References

  • IDF Diabetes Atlas. International Diabetes Federation (4th Edition). International Diabetes Federation, Brussels, Belgium (2009).
  • American diabetes association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31(3), 1–20 (2008).
  • Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol. Ther.10(Suppl. 1), S72–S81 (2008).
  • International Bank for Reconstruction and Development, The World Bank. (2005) International Comparision Program. Preliminary Results. The World Bank, Washington DC, USA (2007).
  • Zhang PP, Engelgau MMM, Norris SLM et al. Application of economic analysis to diabetes and diabetes care. Ann. Intern. Med.140(11), 972–977 (2004).
  • Cefalu W. Economics of diabetes – cost impact of not treating diabetes early and intensively. Clin. Cornerstone6(2), 51–58 (2004).
  • Goldfarb N, Weston C, Hartmann CW et al. Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. Dis. Manag.7(1), 61–75 (2004).
  • Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med.344(18), 1343–1350 (2001).
  • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med.358(6), 580–591 (2008).
  • Ribisl PM, Lang W, Jaramillo SA et al. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with Type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care30(10), 2679–2684 (2007).
  • Loveman E, Frampton GK, Clegg AJ. The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review. Health Technol. Assess.12(9), 1–116 (2008).
  • Christensen NK, Williams P, Pfister R. Cost Savings and clinical effectiveness of an extension service diabetes program. Diabetes Spectr.17(3), 171–175 (2004).
  • Mortimer D, Kelly J. Economic evaluation of the good life club intervention for diabetes self-management. Aus. J. Primary Health12(1), 91–100 (2006).
  • IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Federation, Brussels, Belgium (2005).
  • American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care32(Suppl. 1), S13–S61 (2009).
  • National Collaborating Centre For Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Royal College of Physicians, London, UK (2009).
  • Colagiuri S, Dickinson S, Girgis S, Colagiuri R. National Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the NHMRC. Canberra, ACT, Australia (2009).
  • Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics15(6), 583–595 (1999).
  • Brouwer WB, Koopmanschap MA. How to calculate indirect costs in economic evaluations. Pharmacoeconomics13(5 Pt 1), 563–569 (1998).
  • DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. the Diabetes Control and Complications Trial research group. N. Engl. J. Med.329(14), 977–986 (1993).
  • Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353(25), 2643–2653 (2005).
  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet352(9131), 837–853 (1998).
  • Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35), prospective observational study. BMJ321(7258), 405–412 (2000).
  • Singer DE, Coley CM, Samet JH, Nathan DM. Tests of glycemia in diabetes mellitus. Their use in establishing a diagnosis and in treatment. Ann. Intern. Med.110(2), 125–137 (1989).
  • Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N. Engl. J. Med.310(6), 341–346 (1984).
  • Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care18(4), 440–447 (1995).
  • Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol. Ther.11(10), 623–633 (2009).
  • Weinstein MC, Toy EL, Sandberg EA et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health4(5), 348–361 (2001).
  • American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care27(9), 2262–2265 (2004).
  • Weinstein MC. A Report of the ISPOR Health Science Committee – Task Force on Good Research Practices – Modeling Studies. (2005).
  • Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care30(6), 1638–1646 (2007).
  • Broome J. Trying to value a life. J. Pub. Econ.9, 91–100 (1982).
  • Karlsson G, Johannesson M. The decision rules of cost–effectiveness analysis. Pharmacoeconomics9(2), 113–120 (1996).
  • Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ.16(1), 1 (1997).
  • Olsen JA. Theories of justice and their implications for priority setting in health care. J. Health Econ.16(6), 625–639 (1997).
  • Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J. Pub. Econ.2, 147–157 (1973).
  • Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics24(11), 1121–1131 (2006).
  • Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost–effectiveness threshold. J. Health Serv. Res. Policy11(1), 46–51 (2006).
  • Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics19(6), 609–621 (2001).
  • Nuijten MJ, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics20(12), 855–867 (2002).
  • Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health7(1), 1–10 (2004).
  • Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev. Pharmacoeconomics Outcomes Res.5(1), 65–79 (2005).
  • Sendi PP, Briggs AH. Affordability and cost–effectiveness: decision-making on the cost–effectiveness plane. Health Econ.10(7), 675–680 (2001).
  • Hirth RA, Chernew ME, Miller E et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20(3), 332–342 (2000).
  • Kaplan R, Bush J. Health related quality of life measurement for evaluation research and policy analysis. Health Psychol.1, 61–80 (1982).
  • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ146(4), 473–481 (1992).
  • Stevens A, Colin-Jones D, Gabbay J. ‘Quick and clean’: authoritative health technology assessment for local health care contracting. Health Trends27(2), 37–42 (1995).
  • Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ.13(5), 437–452 (2004).
  • George B, Harris A, Mitchell A. Cost–effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics19(11), 1103–1109 (2001).
  • Council for Public Health and Health Care. Sensible and Sustainable Care. Recommendations by the Council for Public Health and Health Care to the Minister of Health, Wefare and Sports (2006).
  • Dardis R. The value of life: new evidence from the marketplace. Am. Econ. Rev.70(5), 1077–1082 (1980).
  • Ippolito P, Ippolito R. Measuring the value of live saving from consumer reactions to new information. J. Pub. Econ.25, 53–81 (1984).
  • Lanoie P, Pedro C, Latour R. The value of a statistical life: a comparision of two approaches. J. Risk Uncertain.10, 235–257 (1995).
  • Miller T. Variations between countries in values of statistical life. J. Transport Econ. Pol.34(2), 169–188 (2000).
  • Mrozek J, Taylor L. What determines the value of life? A meta-analysis. J. Pol. Anal. Manage.21(2), 253–270 (2002).
  • Tengs T, Adams M, Pliskin J et al. Five-hundred life-saving interventions and their cost–effectiveness. Risk Anal.15(3), 369–390 (1995).
  • Viscusi W, Aldy J. The Value of a Statistical Life: a Critical Review of Market Estimates Throughout the World. NBER Working Paper 9487, MA, USA (2003).
  • The World Bank. World Development Report. The World Bank, Washington, DC, USA (1993).
  • Anand S, Hanson K. Disability-adjusted life years: a critical review. J. Health Econ.16(6), 685–702 (1997).
  • Arnesen T, Nord E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ319(7222), 1423–1425 (1999).
  • Drummond M, Torrance G, Mason J. Cost–effectiveness league tables: more harm than good? Soc. Sci. Med.37(1), 33–40 (1993).
  • Sach TH, Smith RD, Whynes DK. A ‘league table’ of contingent valuation results for pharmaceutical interventions: a hard pill to swallow? Pharmacoeconomics25(2), 107–127 (2007).
  • Luce BR, Mauskopf J, Sloan FA et al. The return on investment in health care: from 1980 to 2000. Value Health9(3), 146–156 (2006).
  • Mc Kee M, Nolte E, Suhrcke M. The Value of Health Improvements in the European Union. London School of Hygiene and Tropical Medicine, London, UK (2005).
  • Nordhaus W, Tobin J. Is Growth Obsolete? Columbia University Press, NY, USA (1972).
  • Daly HE, Cobb J. For the Common Good. Redirecting the Economy Toward Community, the Environment and a Sustainable Future. Beacon Press, MA, USA (1994).
  • Ul Haq M. Reflections on Human Development. Oxford University Press, NY, USA (1995).
  • King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med. Decis. Making25(6), 667–677 (2005).
  • Guria J, Leung J, Jones-Lee M, Loomes G. The willingness to accept value of statistical life relative to the willingness to pay value: evidence and policy implications. Environmental Res. Econ.32(1), 113–127 (2005).
  • Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy74(1), 77–84 (2005).
  • Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics23(5), 423–432 (2005).
  • Richardson J, Smith RD. Calculating society’s willingness to pay for a QALY: key questions for discussion . Appl. Health Econ. Health Policy3(3), 125–116 (2004).
  • Philipson T, Becker G, Goldman D, Murphy K. Terminal care and the value of life near its end. The Milton Friedman Institute For Research in Economics, Report No.: MFI Working Paper Series Chicago, IL, USA (2010).
  • Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ148(6), 913–917 (1993).
  • Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: should ‘reasonable decisions’ lead to uncontrolled growth in expenditures? CMAJ168(7), 849–851 (2003).
  • Suhrcke M, Mc Kee M, Sauto-Arce R et al.The Contribution of Health to the Economy in the European Union. Office for Pfficial Publications of the European Communities Luxembourg (2005).
  • Nordhaus W. The health of nations: the contribution of improved health to living standards. In: The Measurement of Economic and Social Performance. Moss M (Eds). Columbia University Press for National Bureau of Economic Research, NY, USA (2003).
  • Shillcutt S, Walker D, Goodman C, Mills A. Cost effectiveness in low- and middle-income countries. A review of the debates surrounding decision rules. Pharmacoeceonomics27(11), 903–917 (2009).
  • Ham C. Retracing the Oregon trail: the experience of rationing and the Oregon health plan. BMJ316(7149), 1965–1969 (1998).
  • Blumstein JF. The Oregon experiment: the role of cost–benefit analysis in the allocation of Medicaid funds. Soc. Sci. Med.45(4), 545–554 (1997).
  • Dolan P, Metcalfe R, Munro V, Christensen M. Valuing lives and life years: anomalies, implications, and an alternative. Health Econ. Pol. Law3, 277–300 (2008).
  • Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost–effectiveness analysis. Health Policy Plan16(3), 326–331 (2001).
  • Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost–effectiveness from multinational clinical trials. Health Econ.7(6), 481–493 (1998).
  • Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat. Med.22(12), 1955–1976 (2003).
  • Pinto EM, Willan AR, O’Brien BJ. Cost–effectiveness analysis for multinational clinical trials. Stat. Med.24(13), 1965–1982 (2005).
  • Manca A, Willan A. Lost in translation: accounting for between-country differences in the analysis of multinational cost–effectiveness data. Pharmacoeconomics24(11), 1101–1119 (2006).
  • Willan AR, Pinto EM, O’Brien BJ et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ.14(4), 327–338 (2005).
  • Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost–effectiveness analysis: the use of multilevel models. Health Econ.14(5), 471–485 (2005).
  • Hopkins S, Varjonen S. Development of Health-Specific Purchasing Power Parities: General Principles and Problems in Measurement of Health Services Across Countries. OECD Report No.: DELSA/HEA/HA/PPP (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.